Viability by MRI or PET Would Not Have Changed the Results of the STICH Trial

Progress in Cardiovascular Diseases

Volumn 55, Issue 5, 2013, Pages 494-497

  Asrani, Nina S ^a   Chareonthaitawee, Panithaya ^a   Pellikka, Patricia A ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Cardiac imaging; Dobutamine echocardiography; Myocardial viability; Nuclear perfusion imaging; STICH trial viability substudy

Indexed keywords

DOBUTAMINE;

ARTICLE; CARDIAC IMAGING; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSTIC ACCURACY; DRUG DOSE COMPARISON; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BLOOD FLOW; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; ISCHEMIC CARDIOMYOPATHY; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; CORONARY ARTERY BYPASS; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY, STRESS; EVALUATION STUDIES AS TOPIC; FEMALE; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TISSUE SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84875237991     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.09.004     Document Type: Article

References (16)

1. Bonow R.O., Maurer G., Lee K.L., et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Eng J Med 2011, 364:1617-1625.
2. Pellikka P.A., Nagueh S.F., Elhendy A.A., Kuehl C.A., Sawada S.G. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007, 20:1021-1041.
3. Afridi I., Grayburn P.A., Panza J.A., Oh J.K., Zoghbi W.A., Marwick T.H. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 1998, 32:921-926.
4. Baer F.M., Voth E., Schneider C.A., Theissen P., Schicha H., Sechtem U. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995, 91:1006-1015.
5. Cwajg J.M., Cwajg E., Nagueh S.F., et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation: relation to rest-redistribution T1-201 tomography and dobutamine stress echocardiography. J Am Coll Cardiol 2000, 35:1152-1161.
6. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000, 343:1445-1453.
7. Shimoni S., Frangogiannis N.G., Aggeli C.J., et al. Identification of hibernating myocardium with quantitative intravenous myocardial contrast echocardiography: comparison with dobutamine echocardiography and thallium-201 scintigraphy. Circulation 2003, 107:538-544.
8. Pagano D., Bonser R.S., Townend J.N., Ordoubadi F., Lorenzoni R., Camici P.G. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998, 79:281-288.
9. Go R.T., O'Donnell J.K., Underwood D.A., et al. Comparison of gated cardiac MRI and 2D echocardiography of intracardiac neoplasms. AJR Am J Roentgenol 1985, 145:21-25.
10. Schinkel A.F., Bax J.J., Poldermans D., Elhendy A., Ferrari R., Rahimtoola S.H. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007, 32:375-410.
11. Wu K.C., Lima J.A.C. Noninvasive imaging of myocardial viability: current techniques and future developments. Circulation 2003, 93:1146-1158.
12. Knuuti J., Schelbert H.R., Bax J.J. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med 2002, 29:1257-1266.
13. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002, 39:1151-1158.
14. Chareonthaitawee P., Gersh B.J., Araoz P.A., Gibbons R.J. Revascularization in severe left ventricular dysfunction: the role of viability testing. J Am Coll Cardiol 2005, 46:567-574.
15. Ling L.H., Christian T.F., Mulvagh S.L., et al. Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography. Am Heart J 2006, 151:882-889.
16. Siebelink H.M., Blanksma P.K., Crijns H.J., et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 2001, 37:81-88.